Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice

被引:318
作者
Duan, WZ
Guo, ZH
Jiang, HY
Ware, M
Li, XJ
Mattson, MP
机构
[1] NIA, Neurosci Lab, Baltimore, MD 21224 USA
[2] NIA, Comparat Med Sect, Baltimore, MD 21224 USA
[3] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA
[4] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA
关键词
apoptosis; diabetes; Huntington's disease; striatum;
D O I
10.1073/pnas.0536856100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In addition to neurological deficits, Huntington's disease (HD) patients and transgenic mice expressing mutant human huntingtin exhibit reduced levels of brain-derived neurotrophic factor, hyperglycemia, and tissue wasting. We show that the progression of neuropathological (formation of huntingtin inclusions and apoptotic protease activation), behavioral (motor dysfunction), and metabolic (glucose intolerance and tissue wasting) abnormalities in huntingtin mutant mice, an animal model of HD, are retarded when the mice are maintained on a dietary restriction (DR) feeding regimen resulting in an extension of their life span. DR increases levels of brain-derived neurotrophic factor and the protein chaperone heat-shock protein-70 in the striatum and cortex, which are depleted in HD mice fed a normal diet. The suppression of the pathogenic processes by DR in HD mice suggests that mutant huntingtin promotes neuronal degeneration by impairing cellular stress resistance, and that the body wasting in HD is driven by the neurodegenerative process. Our findings suggest a dietary intervention that may suppress the disease process and increase the life span of humans that carry the mutant huntingtin gene.
引用
收藏
页码:2911 / 2916
页数:6
相关论文
共 65 条
  • [1] Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease
    Andreassen, OA
    Dedeoglu, A
    Ferrante, RJ
    Jenkins, BG
    Ferrante, KL
    Thomas, M
    Friedlich, A
    Browne, SE
    Schilling, G
    Borchelt, DR
    Hersch, SM
    Ross, CA
    Beal, MF
    [J]. NEUROBIOLOGY OF DISEASE, 2001, 8 (03) : 479 - 491
  • [2] ANDREW SE, 1993, NAT GENET, V7, P513
  • [3] Striatal glucose metabolism and dopamine D-2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
    Antonini, A
    Leenders, KL
    Spiegel, R
    Meier, D
    Vontobel, P
    WeigellWeber, M
    SanchezPernaute, R
    deYebenez, JG
    Boesiger, P
    Weindl, A
    Maguire, RP
    [J]. BRAIN, 1996, 119 : 2085 - 2095
  • [4] REPLICATION OF THE NEUROCHEMICAL CHARACTERISTICS OF HUNTINGTONS-DISEASE BY QUINOLINIC ACID
    BEAL, MF
    KOWALL, NW
    ELLISON, DW
    MAZUREK, MF
    SWARTZ, KJ
    MARTIN, JB
    [J]. NATURE, 1986, 321 (6066) : 168 - 171
  • [5] IMPROVING DIAGNOSIS OF HUNTINGTONS-DISEASE BY ANALYSIS OF AN INTRAGENIC TRINUCLEOTIDE REPEAT EXPANSION
    BEILBY, J
    CHIN, CY
    PORTER, I
    WALPOLE, IR
    GOLDBLATT, J
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1994, 161 (06) : 356 - 360
  • [6] Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer
    Bemelmans, AP
    Horellou, P
    Pradier, L
    Brunet, I
    Colin, P
    Mallet, J
    [J]. HUMAN GENE THERAPY, 1999, 10 (18) : 2987 - 2997
  • [7] BENITEZ J, 1994, HUM GENET, V94, P563
  • [8] Trinucleotide repeat length and clinical progression in Huntington's disease
    Brandt, J
    Bylsma, FW
    Gross, R
    Stine, OC
    Ranen, N
    Ross, CA
    [J]. NEUROLOGY, 1996, 46 (02) : 527 - 531
  • [9] Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO
  • [10] 2-V